biomarkers for glp-1 agonists Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Frontiers | GLP-1 Receptor Agonists:

Respondents had an average age of 42.6 years and were 54.4% female, 45.1% male, and 0.5% nonbinary, representing all 50 states and the District of Columbia

Compared with GLP-1 RAs, MBS was associated with 25% fewer inpatient stays (mean [SE] stays, 0.016 [0.001] vs 0.012 [0.001]

Finally, the biology of non-response and therapeutic resistance - including the role of gut microbiome composition, adipose tissue dysfunction phenotypes, and genetic determinants of drug metabolism - represents a frontier for translational investigation to improve patient outcomes

People often see corporate medical research as different from academic research and while the goal is slightly differentproducing a medicine versus focusing on advancing knowledgethe science is driven by the same factors: opportunity, curiosity and leveraging whats available

Kovell LC, Juraschek SP, Michos ED

doi: 10.1007/s00125-011-2232-3 55 PangJFengJNLingWJinT